Results 11 to 20 of about 52,225 (202)

Stat5 is indispensable for the maintenance of bcr/abl ‐positive leukaemia

EMBO Molecular Medicine, 2010
Tumourigenesis caused by the Bcr/Abl oncoprotein is a multi-step process proceeding from initial to tumour-maintaining events and finally results in a complex tumour-supporting network. A key to successful cancer therapy is the identification of critical functional nodes in an oncogenic network required for disease maintenance.
Hoelbl, Andrea, Schuster, Christian, Kovacic, Boris, Zhu, Bingmei, Wickre, Mark, Hoelzl, Maria A, Fajmann, Sabine, Grebien, Florian, Warsch, Wolfgang, Stengl, Gabriele, Hennighausen, Lothar, Poli, Valeria, Beug, Hartmut, Moriggl, Richard, Sexl, Veronika   +14 more
openaire   +3 more sources

Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia [PDF]

Leukemia, 2010
Dasatinib is a potent dual Abl/Src inhibitor approved for treatment of Philadelphia chromosome-positive (Ph-positive) leukemias. At a once-daily dose and a relatively short half-life of 3-5 h, tyrosine kinase inhibition is not sustained. However, transient inhibition of K562 leukemia cells with a high-dose pulse of dasatinib or long-term treatment with
Fei, F, Stoddart, S, Müschen, M, Kim, Y-M, Groffen, J, Heisterkamp, N   +5 more
openaire   +5 more sources

The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias [PDF]

Cell Death & Differentiation, 2008
Bcr-Abl tyrosine kinase (TK) inhibitors are promising therapeutic agents for Bcr-Abl-positive (Bcr-Abl(+)) leukemias. Although they are known to promote caspase-mediated apoptosis, it remains unclear whether caspase-independent cell death-inducing mechanisms are also triggered.
Y, Kamitsuji, J, Kuroda, S, Kimura, S, Toyokuni, K, Watanabe, E, Ashihara, H, Tanaka, Y, Yui, M, Watanabe, H, Matsubara, Y, Mizushima, Y, Hiraumi, E, Kawata, T, Yoshikawa, T, Maekawa, T, Nakahata, S, Adachi   +16 more
openaire   +3 more sources

Targeting HSPA8 to repress GPX4 and induce ferroptosis in BCR-ABL positive leukemia

Biomedical Technology
BCR-ABL positive (BCR-ABL+) leukemia is driven by constitutive activation of tyrosine kinase activity, with tyrosine kinase inhibitors (TKIs) serving as the standard treatment. However, resistance to TKIs remains a significant clinical challenge. In this
Shuxin Zhong, Dingrui Nie, Xueting Peng, Kangjie Qiu, Jinyi Liu, Zhangshuai Dai, Xianfeng Zha, Songnan Sui, Weini Li, Weizhang Wang, Cunte Chen, Yangqiu Li, Chengwu Zeng   +12 more
doaj   +3 more sources

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition. [PDF]

J Hematol Oncol, 2020
Background The Philadelphia chromosome (Ph), which leads to the creation and expression of the fusion gene product BCR-ABL, underlines the pathogenesis of chronic myelogenous leukemia (CML) and a fraction of adult and pediatric acute B-lymphoblastic ...
Xiao X, Liu P, Li D, Xia Z, Wang P, Zhang X, Liu M, Liao L, Jiao B, Ren R.   +9 more
europepmc   +2 more sources

BCR-ABL Positive Childhood Chronic Myeloid Leukemia

Journal of Case Reports, 2017
Background : Chronic myeloid leukemia (CML) is a rare disease entity in the pediatric age group constituting about 3-5% of childhood leukemia. The natural history and biologic characteristics of the disease are similar to adult CML.
Timothy A. Ekwere, Emmanuel K. Abudu
openaire   +3 more sources

Aleukemic bcr-abl positive granulocytic sarcoma [PDF]

Leukemia Research, 2009
Granulocytic sarcoma (GS) can occur de novo or in association with intramedullary myeloid disorders. With the advent of sophisticated molecular detection techniques to detect diagnostic genes such as bcr-abl, PML-RARA and CBFB/MYH11 in bone marrow or peripheral blood, many cases of the so called 'primary' GS are questionable.
Kuan, Jew-Win, Pathmanathan, Rajadurai, Chang, Kian Meng, Tan, Sen Mui   +3 more
openaire   +3 more sources

BCR-ABL affects STAT5A and STAT5B differentially. [PDF]

PLoS ONE, 2014
Signal transducers and activators of transcription (STATs) are latent cytoplasmic transcription factors linking extracellular signals to target gene transcription. Hematopoietic cells express two highly conserved STAT5-isoforms (STAT5A/STAT5B), and STAT5
Michael Schaller-Schönitz, David Barzan, Andrew J K Williamson, John R Griffiths, Iris Dallmann, Karin Battmer, Arnold Ganser, Anthony D Whetton, Michaela Scherr, Matthias Eder   +9 more
doaj   +1 more source

Grb10 is involved in BCR-ABL-positive leukemia in mice [PDF]

Leukemia, 2014
The SH2-containing adaptor protein Grb10 was first identified in a yeast screen as a new binding partner for BCR-ABL and associates with BCR-ABL in a tyrosine-dependent manner. However, its function in BCR-ABL-mediated leukemogenesis in vivo is still unknown.
Illert, Anna Lena, Albers, Corinna, Kreutmair, Stefanie, Leischner, Hannes, Peschel, Christian, Miething, Cornelius, Duyster, Justus   +6 more
openaire   +3 more sources

The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia. [PDF]

PLoS Genetics, 2015
The hallmark of Philadelphia chromosome positive (Ph(+)) leukemia is the BCR/ABL kinase, which is successfully targeted by selective ATP competitors. However, inhibition of BCR/ABL alone is unable to eradicate Ph(+) leukemia.
Anahita Rafiei, Afsar Ali Mian, Claudia Döring, Anna Metodieva, Claudia Oancea, Frederic B Thalheimer, Martin Leo Hansmann, Oliver Gerhard Ottmann, Martin Ruthardt   +8 more
doaj   +1 more source